(Q77833640)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10355566%20AND%20SRC:MED&resulttype=core&format=json

8 December 2019

0 references

1 reference

title

Treatment for poor prognosis metastatic germ-cell tumours: much heat but, as yet, little light (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10355566%20AND%20SRC:MED&resulttype=core&format=json

8 December 2019

author name string

D A Anthoney

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10355566%20AND%20SRC:MED&resulttype=core&format=json

8 December 2019

S B Kaye

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10355566%20AND%20SRC:MED&resulttype=core&format=json

8 December 2019

publication date

1 March 1999

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10355566%20AND%20SRC:MED&resulttype=core&format=json

8 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10355566%20AND%20SRC:MED&resulttype=core&format=json

8 December 2019

volume

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10355566%20AND%20SRC:MED&resulttype=core&format=json

8 December 2019

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10355566%20AND%20SRC:MED&resulttype=core&format=json

8 December 2019

page(s)

255-258

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10355566%20AND%20SRC:MED&resulttype=core&format=json

BOMP/EPI intensive alternating chemotherapy for IGCCC poor-prognosis germ-cell tumors: The Spanish Germ-Cell Cancer Group experience (GG)

8 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008369614634

7 January 2021

International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008369614634

7 January 2021

Dose-response and dose-survival advantage for high versus low-dose cisplatin combined with vinblastine and bleomycin in disseminated testicular cancer a southwest oncology group study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008369614634

7 January 2021

Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: a Southeastern Cancer Study Group and Southwest Oncology Group protocol

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008369614634

7 January 2021

DNA flow cytometry in human testicular cancer.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008369614634

7 January 2021

Vincristine, cisplatin, and bleomycin with surgery in the management of advanced metastatic nonseminomatous testis tumors

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008369614634

7 January 2021

Intensive induction chemotherapy for poor risk non-seminomatous germ cell tumours

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008369614634

7 January 2021

Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumor: a Randomized Medical Research Council/European Organization for Research and Treatment of C

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008369614634

7 January 2021

Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008369614634

7 January 2021

Four cycles of BEP vs four cycles of VIP in patients with intermediate-prognosis metastatic testicular non-seminoma: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group. European Organization for Research and Treatment of Ca

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008369614634

7 January 2021

A phase II trial of VP-16, ifosfamide, cisplatin, vinblastine, and bleomycin in advanced germ-cell tumors

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008369614634

7 January 2021

Four cycles of BEP versus an alternating regime of PVB and BEP in patients with poor-prognosis metastatic testicular non-seminoma; a randomised study of the EORTC Genitourinary Tract Cancer Cooperative Group

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008369614634

7 January 2021

Treatment of men with metastatic non-seminomatous germ cell tumours with cyclical POMB/ACE chemotherapy.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008369614634

7 January 2021

POMB/ACE chemotherapy in non-seminomatous germ cell tumours: outcome and importance of dose intensity

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008369614634

7 January 2021

Phase II study of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008369614634

7 January 2021

Phase II trial of paclitaxel shows antitumor activity in patients with previously treated germ cell tumors

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008369614634

7 January 2021

Identifiers

DOI

10.1023/A:1008369614634

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10355566%20AND%20SRC:MED&resulttype=core&format=json

8 December 2019

1 reference